Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
PLoS One. 2012;7(6):e39409. doi: 10.1371/journal.pone.0039409. Epub 2012 Jun 29.
Among birch pollen allergic patients up to 70% develop allergic reactions to Bet v 1-homologue food allergens such as Api g 1 (celery) or Dau c 1 (carrot), termed as birch pollen-related food allergy. In most cases, specific immunotherapy with birch pollen extracts does not reduce allergic symptoms to the homologue food allergens. We therefore genetically engineered a multi-allergen chimer and tested if mucosal treatment with this construct could represent a novel approach for prevention of birch pollen-related food allergy.
BALB/c mice were poly-sensitized with a mixture of Bet v 1, Api g 1 and Dau c 1 followed by a sublingual challenge with carrot, celery and birch pollen extracts. For prevention of allergy sensitization an allergen chimer composed of immunodominant T cell epitopes of Api g 1 and Dau c 1 linked to the whole Bet v 1 allergen, was intranasally applied prior to sensitization.
Intranasal pretreatment with the allergen chimer led to significantly decreased antigen-specific IgE-dependent β-hexosaminidase release, but enhanced allergen-specific IgG2a and IgA antibodies. Accordingly, IL-4 levels in spleen cell cultures and IL-5 levels in restimulated spleen and cervical lymph node cell cultures were markedly reduced, while IFN-γ levels were increased. Immunomodulation was associated with increased IL-10, TGF-β and Foxp3 mRNA levels in NALT and Foxp3 in oral mucosal tissues. Treatment with anti-TGF-β, anti-IL10R or anti-CD25 antibodies abrogated the suppression of allergic responses induced by the chimer.
Our results indicate that mucosal application of the allergen chimer led to decreased Th2 immune responses against Bet v 1 and its homologue food allergens Api g 1 and Dau c 1 by regulatory and Th1-biased immune responses. These data suggest that mucosal treatment with a multi-allergen vaccine could be a promising treatment strategy to prevent birch pollen-related food allergy.
在桦树花粉过敏患者中,多达 70%的患者对 Bet v 1 同源食物过敏原(如 Api g 1 [芹菜]或 Dau c 1 [胡萝卜])产生过敏反应,称为桦树花粉相关食物过敏。在大多数情况下,桦树花粉提取物的特异性免疫疗法并不能减轻对同源食物过敏原的过敏症状。因此,我们对一种多过敏原嵌合体进行了基因工程改造,并测试了这种构建体的黏膜治疗是否可以成为预防桦树花粉相关食物过敏的新方法。
BALB/c 小鼠用 Bet v 1、Api g 1 和 Dau c 1 的混合物进行多敏化,然后用胡萝卜、芹菜和桦树花粉提取物进行舌下挑战。为了预防过敏致敏,在致敏前将由 Api g 1 和 Dau c 1 的免疫显性 T 细胞表位与整个 Bet v 1 过敏原连接而成的过敏原嵌合体经鼻内应用。
鼻内预处理过敏原嵌合体导致抗原特异性 IgE 依赖性β-己糖胺酶释放显著减少,但增强了过敏原特异性 IgG2a 和 IgA 抗体。因此,脾细胞培养物中 IL-4 水平和再次刺激的脾和颈淋巴结细胞培养物中 IL-5 水平明显降低,而 IFN-γ 水平升高。免疫调节与 NALT 中 IL-10、TGF-β 和 Foxp3 mRNA 水平以及口腔黏膜组织中 Foxp3 的增加有关。用抗 TGF-β、抗 IL10R 或抗 CD25 抗体治疗可消除嵌合体诱导的过敏反应的抑制作用。
我们的结果表明,过敏原嵌合体的黏膜应用导致针对 Bet v 1 及其同源食物过敏原 Api g 1 和 Dau c 1 的 Th2 免疫反应减少,这是通过调节和 Th1 偏向的免疫反应实现的。这些数据表明,用多过敏原疫苗进行黏膜治疗可能是预防桦树花粉相关食物过敏的一种有前途的治疗策略。